SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Cytokinetics, Incorporated Common Stock and Sets a Lead Plaintiff Deadline of November 17, 2025

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, alleging that the company made materially false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten, which misled investors about the regulatory timeline [1][2]. Group 1: Lawsuit Details - The lawsuit, Judah Seidman v. Cytokinetics, Incorporated, was initiated in the United States District Court for the Northern District of California for individuals who purchased Cytokinetics common stock between December 27, 2023, and May 6, 2025 [1]. - Class members are notified that they have until November 17, 2025, to request to be appointed as lead plaintiff, although sharing in any recovery does not require serving as a lead plaintiff [4]. Group 2: Allegations Against Cytokinetics - The complaint states that Cytokinetics misrepresented the expected approval timeline from the FDA for aficamten, claiming approval in the second half of 2025 without disclosing risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [2]. - During an earnings call on May 6, 2025, it was revealed that the company had discussions with the FDA regarding safety monitoring but chose to submit the NDA without a REMS, indicating a reckless decision that misled investors [3]. Group 3: Impact on Investors - As a result of the misleading statements, investors purchased Cytokinetics' common stock at inflated prices and faced significant losses when the truth about the regulatory process was disclosed [4].